Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Pediatr Blood Cancer. 2019 May 2;66(8):e27790. doi: 10.1002/pbc.27790

Fig. 4.

Fig. 4

A. Inhibition of AKT and ERK1/2 phosphorylation in KLA cells and human lymphatic endothelial cells (LEC) treated with inhibitors. Western blot analysis was performed on cell lysates (10μg total protein) from KLA cells (1607, 1528, 2360) and LEC, after treatment (1 hour) with either DMSO vehicle (control), PI3K inhibitors LY294002 (10μM) and BYL719 (10μM), AKT inhibitor ARQ092 (5μM), rapamycin (15nM) or MAPK inhibitor U0126 (10μM). Blots were probed with antibodies to phosphorylated-AKT (pSer473), total AKT, p-ERK1/2, total ERK and actin. B. KLA cells and LEC were plated on fibronectin-coated plates in EGM-2MV media. After plating (5 hours) the media was changed to media containing either DMSO vehicle (control), PI3K inhibitors LY294002 (10μM) and BYL719 (5μM), AKT inhibitor ARQ092 (5μM), rapamycin (15nM) or MAPK inhibitor U0126 (10μM). Proliferation was measured using SRB assay 72 hours after treatment with inhibitors. Data represents the results from 3 independent experiments and show percent inhibition compared to vehicle control.